SABCS 2021 – Wrap-Up

Several novel breast cancer therapies have come onto the market in recent years, significantly changing the breast cancer landscape, specifically in the metastatic setting. The Pathways Heart Study has looked at cardiovascular outcomes and risk variables from breast cancer treatments. A number of breast cancer risk factors as well as the benefits of physical exercise and aspirin use among breast cancer survivors are discussed in this review. Read More ›

Tucatinib added to trastuzumab and capecitabine resulted in a substantial and permanent improvement of progression-free survival and overall survival for all patients with HER2-positive metastatic breast cancer with brain metastases, as confirmed by results from the HER2CLIMB study. Read More ›

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, shares topics presented at the 2021 San Antonio Breast Cancer Symposium to help empower patients with breast cancer. Read More ›

Tucatinib-containing therapy resulted in a tumor volume reduction of >80%. Tucatinib was found to be highly effective when combined with paclitaxel plus trastuzumab plus pertuzumab. Read More ›

Tyrosine kinase inhibitor (TKI) treatments show equal overall survival and progression-free survival (PFS) benefits in patients with HER2-positive breast cancer with and without brain metastases. Read More ›

The combination regimen of tucatinib, palbociclib, and letrozole in patients with hormone receptor–positive, HER2-positive breast cancer with brain metastases demonstrates an improved central nervous system progression-free survival in a small group of patients. Read More ›

Tucatinib-trastuzumab-capecitabine combination therapy has been shown to double the overall survival in patients with HER2-positive breast cancer with leptomeningeal metastases. Read More ›

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Oncology Practice Management

Learn more about our family of publications.

View Our Publications